This is the problem with trying to develop drugs for depression.
There is no single, universally accepted binary objective chemical measurement for diagnosing depression. Depression is a complex mental health condition with a variety of contributing factors, biological, psychological, and environmental. Thus clinical studies in this field are extremely difficult, as other have said here the safety profile is the positive take away from this trial.
Shareholders still have another bun in the oven so not the end of the world.
Take it easy today folks.
- Forums
- ASX - By Stock
- ACW
- Ann: ACW XanaCIDD phase 2a trial topline results
Ann: ACW XanaCIDD phase 2a trial topline results, page-21
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
-0.004(12.9%) |
Mkt cap ! $73.21M |
Open | High | Low | Value | Volume |
3.0¢ | 3.1¢ | 2.7¢ | $938.0K | 33.18M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 2741829 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 643372 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 2741829 | 0.027 |
10 | 1394588 | 0.026 |
24 | 4563643 | 0.025 |
10 | 2745804 | 0.024 |
3 | 154000 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 643372 | 2 |
0.029 | 3351339 | 11 |
0.030 | 3008038 | 15 |
0.031 | 2250835 | 6 |
0.032 | 1078289 | 5 |
Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online